Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or… | Phase 1 / Phase 2 | withdrawn | Feb 24, 2011 | University of Texas Southwestern Medical Center | Drug shortage | Other (stated, no rule matched) |
| NCT03035253 | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Phase 1 | terminated | Jan 27, 2017 | OncoMed Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03448874 | Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR…(SEALAR) | N/A | withdrawn | Feb 28, 2018 | Sealantis Ltd. | The company will design a new study | Sponsor / business decision |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT00740961 | Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer | — | terminated | Aug 25, 2008 | Case Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT02453490 | Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy… | Phase 3 | terminated | May 25, 2015 | Zhejiang University | difficultly recruiting | Enrollment / accrual |
| NCT02652702 | Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of…(STAPLER) | Phase 2 | terminated | Jan 12, 2016 | Zhejiang University | Not enough patients recruited | Enrollment / accrual |
| NCT00568425 | QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of… | — | terminated | Dec 6, 2007 | Stanford University | Inadequate response to Scientific Review Committee. | Other (stated, no rule matched) |
| NCT04285008 | Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A…(RESCue) | N/A | withdrawn | Feb 26, 2020 | Motus GI Medical Technologies Ltd | Sponsor has terminated study due to COVID-19 related concerns | COVID-19 / pandemic |
| NCT02205307 | A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in…(PILLAR III) | N/A | terminated | Jul 31, 2014 | Novadaq Technologies ULC, now a part of Stryker | Slow recruitment | Enrollment / accrual |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After… | Phase 3 | terminated | Oct 3, 2017 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT03258541 | Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy | N/A | terminated | Aug 23, 2017 | Thomas Zilli | Surgical access not facilitated- residues of hydrogel. | Other (stated, no rule matched) |
| NCT02052921 | Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved… | N/A | terminated | Feb 3, 2014 | Instituto do Cancer do Estado de São Paulo | During the execution time foreseen in the project, the expected number of patients was not reached. | Other (stated, no rule matched) |
| NCT00602329 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab… | Phase 2 | terminated | Jan 28, 2008 | Abramson Cancer Center at Penn Medicine | Due to Poor accrual | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT03705013 | Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01) | — | terminated | Oct 15, 2018 | Exact Sciences Corporation | Sponsor Decision | Sponsor / business decision |
| NCT03487484 | Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With… | — | terminated | Apr 4, 2018 | University Hospital, Basel, Switzerland | insufficient recruitment | Enrollment / accrual |
| NCT00353457 | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally… | Phase 2 | terminated | Jul 18, 2006 | Abramson Cancer Center at Penn Medicine | new studies were finding that Erbitux was not beneficial | Other (stated, no rule matched) |
| NCT00091286 | Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal… | Early Phase 1 | terminated | Sep 9, 2004 | Craig L Slingluff, Jr | Slow accruals | Enrollment / accrual |
| NCT02889276 | Effects of Functional Exercise on Fitness and QoL in Cancer Survivors(RETRACE) | N/A | terminated | Sep 5, 2016 | University of Portsmouth | Only 4 participants were recruited from 130 potential participants. | Enrollment / accrual |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy…(UFT RT Phase 3) | Phase 3 | terminated | Sep 21, 2005 | Institut Cancerologie de l'Ouest | Terminated after interim analysis | Efficacy / futility |
| NCT01547923 | Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency…(DPD côlon) | N/A | terminated | Mar 8, 2012 | Institut Cancerologie de l'Ouest | The study stopped due to a death in the arm control | Other (stated, no rule matched) |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and…(McCAVE) | Phase 2 | terminated | May 19, 2014 | Hoffmann-La Roche | not stated | Not stated |
| NCT02797405 | Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay(THEODORA) | N/A | terminated | Jun 13, 2016 | Centre Leon Berard | Withdrawal of analysis study Partner. | Other (stated, no rule matched) |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT03688230 | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic…(AMELION) | Phase 2 | withdrawn | Sep 28, 2018 | SFJ Pharmaceuticals X, LTD. | Co-development decision | Other (stated, no rule matched) |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | terminated | Jan 5, 2012 | Georgetown University | Low accrual--unable to meet accrual goals | Enrollment / accrual |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | Phase 1 | withdrawn | Aug 23, 2018 | Lynkcell Inc. | Unable to recruit individuals for the study | Enrollment / accrual |
| NCT03049124 | Exercise for Adults Diagnosed With Rectal Cancer | N/A | withdrawn | Feb 9, 2017 | University of Ottawa | We were unable to enroll participants into the study. | Enrollment / accrual |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | N/A | terminated | Mar 20, 2012 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00544700 | Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic… | Phase 3 | terminated | Oct 16, 2007 | Swiss Cancer Institute | Data collection is completed. As no changes in the endpoints were expected in the future, no… | Other (stated, no rule matched) |
| NCT03035279 | A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal… | Phase 1 | terminated | Jan 30, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02687009 | A Study of Niclosamide in Patients With Resectable Colon Cancer | Phase 1 | terminated | Feb 22, 2016 | Michael Morse, MD | low accrual | Enrollment / accrual |
| NCT01057017 | First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras | Phase 2 | terminated | Jan 27, 2010 | Brown University | possible lack of efficacy | Efficacy / futility |
| NCT01669720 | Adjuvant Aflibercept for Metastatic Colorectal Cancer(C261) | Phase 2 | terminated | Aug 21, 2012 | Brown University | Lack of efficacy and enrollment | Efficacy / futility |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal…(276) | Phase 1 / Phase 2 | terminated | Aug 23, 2012 | Brown University | pilot data to be used for upcoming larger trial. | Other (stated, no rule matched) |
| NCT03413930 | Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer | N/A | withdrawn | Jan 29, 2018 | Ruijin Hospital | No funding was raised | Funding |
| NCT02523911 | Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy… | N/A | withdrawn | Aug 14, 2015 | MercyOne Des Moines Medical Center | investigator graduated and is not longer at this institution | Investigator |
| NCT00541112 | Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and… | Phase 2 | terminated | Oct 8, 2007 | UNICANCER | Toxicity and lack of efficacy | Safety / toxicity |
| NCT00955240 | Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With… | Phase 2 | terminated | Aug 10, 2009 | UNICANCER | Inadequate toxicity | Safety / toxicity |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of… | Phase 2 | terminated | Apr 24, 2015 | US Oncology Research | insufficient accrual | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03323424 | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients…(IRAM) | Phase 2 | withdrawn | Oct 27, 2017 | Institut de Cancérologie de la Loire | No patient enrolled during the authorized period | Enrollment / accrual |
| NCT01741038 | AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer | Phase 2 / Phase 3 | withdrawn | Dec 4, 2012 | Mirror Biologics, Inc. | moved study to USA | Other (stated, no rule matched) |
| NCT02809846 | Quell Opioid Reduction and Pain Relief in Patients With Cancer | N/A | terminated | Jun 22, 2016 | Scripps Translational Science Institute | Unable to recruit enough participants. | Enrollment / accrual |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | — | terminated | Nov 1, 2006 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01532804 | 2nd-line Treatment of Metastatic Colorectal Cancer(BEVATOMOX) | Phase 2 | terminated | Feb 15, 2012 | Institut du Cancer de Montpellier - Val d'Aurelle | too slow recruiting | Enrollment / accrual |
| NCT02328664 | SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality(SCAPURA) | N/A | terminated | Dec 31, 2014 | Dr. Frank ter Borg MD PhD | Interim analysis showed no added value of second look endoscopy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 27, 2020source: clinicaltrials